Background {#Sec1}
==========

Breast cancer (BC) is the most common malignancy among women worldwide \[[@CR1], [@CR2]\]. The prognosis of this disease mainly depends on its early detection, which currently to a major part relies on mammography. Early detection of this disease can also be facilitated by new diagnostic biomarkers. The current Food and Drug Administration (FDA)-approved blood-based biomarkers for BC, such as CA15-3 and CA27-29, are solely recommended for the monitoring of disease relapse and treatment efficacy, rather than diagnosis \[[@CR3], [@CR4]\]. Specific gene mutation tests, such as *BRCA1/2* mutation analysis, are currently only used for screening of hereditary BC cases, which constitute only about 5--10% of total BC cases \[[@CR5], [@CR6]\]. For women at normal risk of developing BC, many national organizations recommend screening mammography for older women. In the USA, screening mammography is recommended every 2 years for women at age between 50 and 74 \[[@CR7]\]. However, the present screening method is criticized for both low sensitivity \[[@CR8]\] and disadvantages due to over-diagnosis \[[@CR9], [@CR10]\]. Thus, alternative approaches for BC detection or risk stratification are clearly needed.

Both global hypomethylation and silencing of tumor suppressor genes through promoter hypermethylation can come along with tumor development, and both have been recognized as common hallmarks of many cancers \[[@CR11]\]. Similar alterations can also be measured in blood-derived DNA, which suggests the possibility of blood-based DNA methylation markers to serve as new screening markers or markers for risk stratification \[[@CR12], [@CR13]\]. To date, a considerable number of studies on DNA methylation in cancer have used DNA obtained from blood (whole blood or white blood cells) or cell-free DNA (cfDNA) isolated from serum or plasma, with the assessment of differences in methylation levels between BC patients and cancer-free healthy controls, to identify methylation markers \[[@CR14]--[@CR22]\]. A substantial number of studies concluded that BC patients and healthy controls exhibit differential DNA methylation patterns in peripheral blood. However, numerous further studies have reported controversial findings, and clear evidence is still lacking whether DNA methylation changes could serve as biomarker for BC diagnosis or risk stratification.

The aim of this review is to summarize the current evidence on DNA methylation-associated biomarkers for BC risk evaluation or early detection, by performing a comprehensive systematic review of published DNA methylation studies in blood-derived DNA of BC patients in comparison to healthy controls. From each eligible study, we extracted essential information, such as age of study subjects, sample size, applied methylation detection methods, methylation levels of patients and healthy controls, *p* values for methylation differences, and odds ratios (ORs), in order to gain insights into the currently accumulated evidence regarding the use of DNA methylation markers for potential future screening tests.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

A systematic literature search was performed to identify studies assessing DNA methylation changes in blood as biomarkers for risk or early detection of BC. PubMed and ISI Web of Knowledge were searched for eligible articles until 31 January 2016. The following combination of keywords was used: \[breast\] (and) \[cancer (or) neoplasm (or) carcinoma (or) adenoma (or) malignancy (or) adenoma\] (and) \[DNA methylation (or) methylated (or) hypermethylation (or) hypomethylation\] (and) \[risk (or) detection (or) diagnosis\] (and) \[serum (or) blood (or) plasma (or) white blood cell\]. The literature search was limited to studies focusing on humans and published in English.

Eligibility criteria {#Sec4}
--------------------

Duplicate articles were removed upon combining the retrieved publications from the two databases. A first round of selection was conducted by reviewing the titles and abstracts. Only full-text reports of original studies were included, thus meeting abstracts, reviews, and editorials were excluded. Articles not focusing on DNA methylation changes in blood in the context of BC detection/diagnosis/risk prediction were excluded, including studies that analyzed (1) DNA methylation markers in tissue samples, (2) DNA methylation as prognostic markers of BC or predictive markers for BC treatment efficacy, and (3) DNA isolated from collected CTC cells.

After the first round examination, we conducted a full-text review for the remaining articles. In addition, studies that did not include healthy female controls, for example, only with benign breast disease patients, were not considered. Studies were also excluded if the information regarding methylation levels of BC cases and healthy controls or ORs were not reported or could not be extracted from published data, for example, studies that solely presented results by heatmaps or reported the methylation levels of a combination of specific loci/genes. Cross-referencing was used as a possible source for identifying studies related to the present topic.

Data extraction and statistical analysis {#Sec5}
----------------------------------------

Eligible studies were included in the data extraction procedure, which was conducted independently by two investigators (Q. Tang and J. Cheng) with a standardized data extraction form. The following variables were extracted: first author, publication year, study design, age of study subjects, DNA source (whole blood, serum, or plasma), DNA methylation detection method, the type of measured DNA methylation (global or gene/locus specific), and essential results (methylation levels of cases and controls, ORs, *p* values). Any disagreement was resolved by further review and discussion among the coauthors. In case methylation levels were not explicitly reported, the information was extracted from available tables and figures to the possible extent. If not presented in the articles, *p* values for methylation differences between BC cases and healthy controls were calculated by Fisher's exact test. Reporting of data follows the PRISMA statements \[[@CR23]\].

Results {#Sec6}
=======

Literature overview {#Sec7}
-------------------

The process of the systematic literature search is displayed in Fig. [1a](#Fig1){ref-type="fig"}. Briefly, the primary search in PubMed and Web of knowledge identified 945 articles, of which 206 were duplicate articles. After excluding non-eligible articles (see Fig. [1a](#Fig1){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Supplementary materials), 45 articles could be included in this review, including 26 articles used DNA isolated from whole blood \[[@CR14]--[@CR21], [@CR24]--[@CR41]\], two articles used DNA isolated from both whole blood and plasma \[[@CR42], [@CR43]\], six articles used DNA isolated from plasma \[[@CR44]--[@CR49]\], and 11 articles used DNA isolated from serum \[[@CR50]--[@CR60]\] (Table [1](#Tab1){ref-type="table"}). For the studies that used serum or plasma as DNA source, four of them used two centrifugation steps to get serum or plasma \[[@CR42], [@CR45], [@CR47], [@CR48]\] and the rest used one centrifugation step or sample processing procedures are not available (Table [1](#Tab1){ref-type="table"}). The included articles were published between 2004 and 2015.Fig. 1**a** Flow diagram of the literature search process (search until 30.01.2016) and **b** summarize strategy of the review Table 1Characteristics summary of the 45 eligible studiesNumberFirst authorYearCountryDNA sourceSample treatmentMeasurementMethylation levels availableOdds ratio estimation available1Widschwendter M2008GermanyBlood--Gene-specific methylationYesYes2Snell C2008AustraliaBlood--Gene-specific methylationYesNo3Ito Y2008UKBlood--Gene-specific methylationYesYes4Flanagan. JM2009UKBlood--Gene-specific methylationYesYes5Choi JY2009USABlood--Global DNA methylationYesYes6Cho YH2010TurkeyBlood--Both global DNA methylation and gene-specific methylationYesNo7Hoffman AE2010ConnecticutBlood--Gene-specific methylationNoYes8Wong EM2011AustraliaBlood--Gene-specific methylationYesYes9Iwamoto T2011JapanBlood--Gene-specific methylationYesYes10Brennan K2012Australia, New Zealand, UK, and EuropeBlood--Both global DNA methylation and gene-specific methylationYesYes11Xu X2012USABlood--Global DNA methylationYesYes12Bosviel R2012FranceBlood--Gene-specific methylationYesNo13Wu HC2012USABlood--Global DNA methylationYesYes14Delgado-Cruzata L2012USABlood--Global DNA methylationYesYes15Kitkumthorn N2012ThailandBlood--Global DNA methylationYesNo16Hajikhan Mirzaei M2012IranBlood--Gene-specific methylationYesNo17Askari M2013IndiaBlood--Gene-specific methylationYesYes18Severi G2014AustraliaBlood--Global DNA methylationYesYes19Yang RX2014GermanyBlood--Gene-specific methylationYesYes20Kuchiba A2014JapanBlood--Global DNA methylationYesYes21Gupta S2014PolandBlood--Gene-specific methylationYesYes22DeRoo LA2014USABlood--Global DNA methylationNoYes23van Veldhoven K2015ItalyBlood--Global DNA methylationYesYes24Cho YH2015USABlood--Gene-specific methylationYesYes25Yari K2015IranBlood--Gene-specific methylationYesNo26Harrison K2015EuropeBlood--Gene-specific methylationYesYes27Zmetakova I2013SlovakiaBlood and plasma1000*g* for 10 min + 1000*g* for 10 minGene-specific methylationYesNo28Enders KN2014ChinaBlood and plasmanaGene-specific methylationYesNo29Hoque MO2006SenegalPlasma2200 rpm for 10--15 minGene-specific methylationYesNo30Papadopoulou E2006GreecePlasma2000 rpm for 10 min + 2000 rpm for 10 minGene-specific methylationYesNo31Yazici H2009USAPlasmanaGene-specific methylationYesNo32Radpour R2011SwitzerlandPlasma16,006*g* for 10 min + full speed 10 minGene-specific methylationYesNo33Enders KO Ng2011ChinaPlasma1600*g* for 10 min + 16,000*g* for 10 minGene-specific methylationYesNo34Chimonidou M2013GreecePlasma2000*g* for 10 minGene-specific methylationYesNo35Dulaimi E2004PennsylvaniaSerumnaGene-specific methylationYesNo36Martinez-Galan J2008SpainSerum2000*g* for 10 minGene-specific methylationYesNo37Van der Auwera I2009BelgiumSerum2000*g* for 10 minGene-specific methylationYesNo38Chen Z2009ChinaSerum1000*g* for 10 minGene-specific methylationYesNo39Zurita M2010SpainSerum2000*g* for 10 minGene-specific methylationYesNo40Ahmed IA2010GermanySerum2000*g* for 10 minGene-specific methylationYesNo41Brooks JD2010USASerumnaGene-specific methylationYesNo42Kim JH2010KoreaSerumnaGene-specific methylationYesNo43Kloten V2013GermanySerum2000*g* for 10 minGene-specific methylationYesNo44Swellam M2015EgyptSerum1600*g* for 15 minGene-specific methylationYesNo45Liu LM2015ChinaSerumnaGene-specific methylationYesNo*na* not available

Among all eligible studies, only 11 studies investigated global DNA methylation. This was always done in DNA isolated from whole blood (Table [1](#Tab1){ref-type="table"}). The majority of studies measured gene- or locus-specific DNA methylation levels, in DNA isolated either from whole blood or in cfDNA isolated from serum or plasma (Table [1](#Tab1){ref-type="table"}). To get a better overview of global DNA methylation changes, as well as the differentially methylated genes between BC patients and healthy controls, we summarize these studies separately, as shown in Fig. [1b](#Fig1){ref-type="fig"}.

Global DNA methylation in peripheral blood of BC cases and controls {#Sec8}
-------------------------------------------------------------------

As shown in Table [2](#Tab2){ref-type="table"}, a total of 15 studies from 11 literatures evaluated global DNA methylation levels in whole blood by different strategies. These included using mean methylation intensities of all Infinium HumanMethylation450K (450 K) probes (*β* value) as global DNA methylation levels, measuring the percentage of methylated DNA by luminometric methylation assay (LUMA) and the concentration of 5-methyldeoxycytosine (5-mdC) by liquid chromatography-mass spectrometry (LC-MS) or measuring the methylation of repetitive DNA elements (i.e., LINE-1, Alu, or Sat2) by pyrosequencing or the MethyLight assay as surrogates of global DNA methylation levels. Among them, four nested case--control studies \[[@CR17]--[@CR19], [@CR38]\] used prospectively collected samples of BC cases and healthy controls, while the remaining studies used samples collected at diagnosis or shortly after diagnosis and healthy controls \[[@CR17], [@CR26], [@CR27], [@CR29], [@CR31]--[@CR33], [@CR36]\]. Case number of these studies was between relative large (over 100 subjects for each group), except the studies by Kitkumthorn N et al. (with 36 cases) \[[@CR33]\] and Cho YH et al. (with 40 cases and 40 controls) \[[@CR27]\]. Cases and controls used in these 14 studies were number- and age-matched.Table 2Global DNA methylation in peripheral blood of breast cancer cases and healthy controlsMeasurementsAuthor, year \[ref\]Study designAssay (value)Case no./control no.Case age/control age (y)^a^Meth (case)Meth (control)*p* valueMain findings*β* valuevan Veldhoven K, 2015 \[[@CR18]\]Nested case--control450 K (EPIC cohort) (mean + SD)162/16254.4/54.253.00 ± 0.3953.18 ± 0.351.82E−05Epigenome-wide hypomethylation of DNA in samples from EPIC cohort.450 K (NOWAC cohort) (mean + SD)168/16855.4/55.454.02 ± 0.4554.02 ± 0.410.79WBGS (BGS cohort) (mean)548/54852/5248.1248.3naSeveri G, 2014 \[[@CR19]\]Nested case--control450 K (mean + SD)420/42064/6451.86 ± 1.0051.95 ± 1.010.006Epigenome-wide hypomethylation of DNA in BC patients.LUMAKuchiba A, 2014 \[[@CR36]\]Case--controlLUMA (% DNA meth)384/38454.1/53.968.9 ± 3.570.2 ± 3.4\<0.01Global genomic hypomethylation in BC patients.Xu X, 2012 \[[@CR29]\]Case--controlLUMA (%)1055/1101na/na57.3 ± 15.752.4 ± 16.7\<0.0001Global promoter hypermethylation in patients.Delgado-Cruzata L, 2012 \[[@CR32]\]Case--controlLUMA (%)263/32149.5/48.067.1 ± 7.667.5 ± 7.3\>0.05LUMA DNA methylation levels were similar between cases and controls.5-mdCChoi JY, 2009 \[[@CR26]\]Case--controlLC-MS (test set) (mean)19/1835--75/35--753.984.330.001Hypomethylation of 5-mdC in BC patients.LC-MS (validation set) (mean)176/17335--75/35--754.18 ± 0.344.38 ± 0.36\<0.001LINE-1Kitkumthorn N, 2012 \[[@CR33]\]Case--controlCOBRA (%)36/14450.28/48.67*4042*\>0.05No significant differences in LINE-1 methylation between BC cases and healthy controls.Xu X, 2012 \[[@CR29]\]Case--controlPyrosequencing (mean)1064/1100na/na78.878.80.94As above.Brennan K, 2012 \[[@CR17]\]Pyrosequencing (mean and IQR)As above.Case--controlBGS cohort241/24254/5479.0 (78.1--79.9)79.0 (77.9--80.1)0.96Case--controlEPIC cohort232/26352/5275.2 (73.9--76.3)75.1 (73.9--76.3)0.89Nested case--controlKConFab cohort153/21850/6076.6 (75.2--77.6)76.0 (74.3--78.0)0.2Wu HC, 2012 \[[@CR31]\]Case--controlMethyLight (%)265/33349.5/48.0107.4 ± 63.6108.5 ± 59.1\>0.05As above.Pyrosequencing (mean)279/34049.5/48.074.5 ± 3.074.5 ± 2.6\>0.05Cho YH, 2010 \[[@CR27]\]Case--controlMethyLight (%)40/4050.8/48.3*7078*\>0.05As above.Choi JY, 2009 \[[@CR26]\]Case--controlPyrosequencing (mean)19/1835--75/35--7574.773.90.176As above.Deroo LA, 2014 \[[@CR38]\]^b^Nested case--controlPyrosequencing294/64657.9/nanananaAs above.Sat2Wu HC, 2012 \[[@CR31]\]Case--controlMethyLight (%)266/33349.5/48.041.3 ± 24.443.5 ± 32.9\>0.05No significant differences in Sat2 methylation between BC cases and healthy controls.Cho YH, 2010 \[[@CR27]\]Case--controlMethyLight (%)40/4050.8/48.3*125150*0.01Hypomethylation of Sat2 inpatients.AluWu HC, 2012 \[[@CR31]\]Case--controlMethyLight (%)266/33449.5/48.095.5 ± 36.698.7 ± 51.5\>0.05No significant differences in Alu methylation between BC cases and healthy controls.Cho YH, 2010 \[[@CR27]\]Case--controlMethyLight (%)40/4050.8/48.3*5861*\>0.05As above.\[3H\]-methylDelgado-Cruzata L, 2012 \[[@CR32]\]Case--control\[3H\]-Methyl acceptance assay233/29549.6/48.297,111 ± 76,34888,030 ± 70,841\<0.05Global genomic hypomethylation in BC patients (more \[3H\]-methyl acceptance).The numbers in italic are extracted from boxplot or scatter plots*450K* Infinium HumanMethylation 450K Beadchips, *WGBS* whole genome bisulfite sequencing, *LUMA* luminometric methylation assay, *COBRA* combined bisulfite restriction analysis, *5-mdC* 5-methyldeoxycytosine, *na* not available^a^Age indicates mean age or range^b^The mean DNA methylation level of BC cases and controls is not available; the study only reported the results of the quartile analysis

As shown in Table [2](#Tab2){ref-type="table"}, studies of van Veldhoven and Severi reported epigenome-wide hypomethylation of blood DNA in BC patients compared to controls, even that van Veldhoven et al. \[[@CR18]\] observed lower methylation in BC cases in one of their study cohorts, but not in another two study cohorts. Three studies \[[@CR29], [@CR32], [@CR36]\] measured the global methylation content by LUMA assay but obtained heterogeneous results. Specifically, Kuchiba et al. \[[@CR36]\] observed an increased global blood DNA methylation in BC patients, while Xu et al. \[[@CR29]\] reported a decrease and Delgado-Cruzata et al. \[[@CR32]\] found no significant methylation differences between BC cases and controls. Choi JY et al. \[[@CR26]\] observed significant lower level of 5-mdC in patients compared to controls. Interestingly, nine studies from seven articles \[[@CR17], [@CR26], [@CR27], [@CR29], [@CR31], [@CR33], [@CR38]\] evaluated the methylation level of LINE-1 repeats with different detection methods, but almost all of them reported that there were no significant difference in LINE-1 methylation between BC cases and controls (Table [2](#Tab2){ref-type="table"}). Studies investigating Sat2 and Alu repetitive elements also revealed inconsistent results (Table [2](#Tab2){ref-type="table"}). Delgado-Cruzata L et al. \[[@CR32]\] observed significant higher \[3H\]-methyl acceptance (lower DNA methylation) in patients than in controls.

Overall, the evidence of global DNA hypo- or hypermethylation in blood DNA of BC cases is so far limited and not conclusive. As shown in Table [2](#Tab2){ref-type="table"}, less than half of these studies reported significant global hypomethylation in blood DNA of BC patients (Table [2](#Tab2){ref-type="table"}) and the overall methylation difference between BC cases and controls are relative small (effect size varied from 0.013 to 0.25). This could be due to the complicated epigenetic background of DNA isolated from whole blood as well as the still high variability of quantitative DNA methylation detection methods. In addition, the eligibility of LINE-1 as surrogate for global DNA methylation level might be limited, as nine studies observed no significant difference of LINE-1 methylation between cases and controls.

Some studies also investigated the associations between blood DNA methylation levels and BC risk by quantile analysis, comparing the risk of women in the highest quantile and that of women in the lowest quantile (Fig. [2a](#Fig2){ref-type="fig"}) or vice versa (Fig. [2b](#Fig2){ref-type="fig"}). As shown in Fig. [2a](#Fig2){ref-type="fig"}, Delgado-Cruzata and coauthors concluded that there was no significant association between global DNA methylation levels detected by LUMA assay and \[3H\]-methyl acceptance assay and BC risk \[[@CR32]\]. Wu HC et al. \[[@CR31]\] and DeRoo LA et al. \[[@CR38]\] evaluated possible associations between the methylation level of repetitive elements (LINE-1, Alu, or Sat2) of blood DNA and BC risk, but also with inconsistent results. Choi et al. used the amounts of 5-mdC as surrogates for global DNA methylation in blood and reported that women representing the lowest 5-mdC quantile had a higher risk of BC (2.81, 95% CI 1.65--4.94), compared with women of the highest quantile \[[@CR26]\]. As shown in Fig. [2b](#Fig2){ref-type="fig"}, Xu et al. \[[@CR29]\] and Kuchiba et al. \[[@CR36]\] revealed a positive association between LUMA methylation level and BC risk. Three large prospective studies were reported in two articles. Here, the global DNA methylation was investigated by 450K methylation arrays. Mean *β* values across the whole genome were calculated and used as global DNA methylation level \[[@CR18], [@CR19]\]. For women in the highest quantile compared to women in the lowest methylation quantile, the ORs (95% CI) were 0.34 (0.18--0.66) (EPIC cohort) and 0.99 (0.56--1.76) (NOWAC cohort) in the study of van Veldhoven et al. \[[@CR18]\], and the ORs were 0.42 (0.20--0.90) in the study of Severi and coauthors \[[@CR19]\]. This suggests that hypomethylation in whole blood might be associated with an increased risk of BC, even the abovementioned results are inconclusive.Fig. 2Associations of global DNA methylation in blood and BC risk. **a** Studies used the highest methylation quantile as reference. **b** Studies used the lowest methylation quantile as reference

Overall, the association between global DNA methylation and BC risk is still unclear, as both positive association and negative association were reported.

Gene-specific methylation in whole blood DNA of BC cases and controls {#Sec9}
---------------------------------------------------------------------

Table [3](#Tab3){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1 list all the studies that examined the methylation levels of specific gene loci in whole blood DNA of BC cases and healthy controls. All of these studies were case--control studies. The number of cases varied from only seven to 1021. The most frequently used methods for detection of gene-specific methylation levels were MethyLight and pyrosequencing. *BRCA1* was investigated in seven studies and thus the most frequently investigated gene \[[@CR16], [@CR20], [@CR24], [@CR27], [@CR30], [@CR37], [@CR39]\]. Importantly, all these studies reported a rather higher frequency of methylated *BRCA1* in BC cases than in healthy controls, although the differences were only statistically significant in four studies \[[@CR16], [@CR20], [@CR24], [@CR37]\]. *ATM* was investigated in two studies \[[@CR15], [@CR17]\], and both of them observed hypermethylation of *ATM* in BC patients. Methylation levels of *IGF2* \[[@CR25], [@CR41]\], *CDH1* \[[@CR39], [@CR42]\], *SYK* \[[@CR14], [@CR42]\], *RARB* \[[@CR27], [@CR39]\], *APC* \[[@CR27], [@CR42]\], and *RASSF1A* \[[@CR27], [@CR42]\] were found similar between BC patients and controls in two or more studies. Methylation of *ESR* \[[@CR14], [@CR42]\] and *TIMP3* \[[@CR14], [@CR42]\] were also determined in more than one study, while the methylation differences of these genes between blood DNA of BC cases and controls were not conclusive. Other genes investigated in only one study were summarized in Additional file [1](#MOESM1){ref-type="media"}: Table S1.Table 3Gene-specific methylation in peripheral blood DNA in breast cancer cases and controls investigated in more than one studyGeneAuthor, year \[ref\]^a^Assay (value)Case no./control no.Case age/control age (y)^b^Meth (case)Meth (control)*p* valueMain findings*BRCA1*Cho YH, 2015 \[[@CR39]\]MethyLight (%)1021/1036na/na1210\>0.05Higher frequency of methylated *BRCA1* in BC patients was observed in all six studies.Gupta S, 2014 \[[@CR37]\]MS-HRM (%)66/3648.8/56.122.75.60.03Bosviel R, 2012 \[[@CR30]\]QMSP (%)902/99047.1/45.947.1 (46.1--48.1)45.9 (45.0--46.8)0.08Wong EM, 2011 \[[@CR20]\]MS-HRM (%)255/169\<40/\<4010.93.60.004Iwamoto T, 2011 \[[@CR16]\]MSP (%)200/20050/5021.513.50.045Cho YH, 2010 \[[@CR27]\]MethyLight (%)40/4050.8/48.385\>0.05Snell C, 2008 \[[@CR24]\]MethyLight (%)7/735--51/35--5142.914.3\<0.05*ATM*Brennan K, 2012 \[[@CR17]\]Pyrosequencing ATM (mvp2a)Hypermethylation of *ATM* (intragenic repetitive element) in BC patients was observed in two studies.BGS cohort (mean and IQR)249/24854/5476.8 (70.9--82.7)76.4 (70.2--80.2)0.02EPIC cohort (mean and IQR)235/28352/5275.7 (70.0--80.8)76.1 (70.5--80.6)0.4KConFab cohort (mean and IQR)156/21050/6081.8 (75.8--86.5)76.9 (71.6--81.5)4.87 × 10^−6^Pyrosequencing ATM (mvp2b)BGS cohort (mean and IQR)248/23454/5491.4 (85.6--95.0)91.0 (87.0--94.8)0.61EPIC cohort (mean and IQR)240/28752/5292.3 (88.3--95.7)92.2 (87.3--95.2)0.36KConFab cohort (mean and IQR)162/20850/6092.3 (82.4--96.5)92.6 (87.2--96.3)0.24Flanagan JM, 2009 \[[@CR15]\]Pyrosequencing (mean and IQR)190/19062.8/62.891.4 (72.8--98.4)89.8 (53.0--98.0)0.002*IGF2*Harrison K, 2015 \[[@CR41]\]Pyrosequencing (mean ± SD)189/36356/5648.94 ± 5.6148.15 ± 5.770.123Two studies reported no significant differences in methylation of *IGF2* between BC cases and healthy controls.Ito Y, 2008 \[[@CR25]\]Pyrosequencing\
(% of loss of methylation)EPIC-Norfolk cohort228/46060.5/60.36.66.30.91ABC cohort338/8452.6/43.25.67.10.65*CDH1*Cho YH, 2015 \[[@CR39]\]MethyLight (%)1021/1036na/na5866\>0.05Three studies observed no significant differences in methylation of *CDH1* between BC cases and controls.Zmetakova I, 2013 \[[@CR42]\]Pyrosequencing (mean ± SD)34/5041--90/20--789.64 ± 2.109.02 ± 1.600.698Cho YH, 2010 \[[@CR27]\]MethyLight (%)40/4050.8/48.388\>0.05*ESR1*Zmetakova I, 2013 \[[@CR42]\]Pyrosequencing (mean ± SD)34/5041--90/20--784.09 ± 1.443.22 ± 0.860.026Zmetakova I et al. reported higher methylation of *ESR1* in patients, while Widschwendter. M et al. observed no significant difference.Widschwendter M, 2008 \[[@CR14]\]MethyLight (%)320/67650--74/50--7412.213.50.645*SYK*Zmetakova I, 2013 \[[@CR42]\]Pyrosequencing (mean ± SD)34/5041--90/20--781.15 ± 0.441.06 ± 0.240.638Both studies observed no significant differences in methylation of *SYK* between BC cases and controls.Widschwendter M, 2008 \[[@CR14]\]MethyLight (%)320/67650--74/50--742.22.40.889*TIMP3*Zmetakova I, 2013 \[[@CR42]\]Pyrosequencing34/5041--90/20--783.65 ± 2.552.50 ± 0.810.036Zmetakova I et al. reported higher methylation of *TIMP3* in patients, while Widschwendter. M et al. observed no significant difference.Widschwendter M, 2008 \[[@CR14]\]MethyLight (%)320/67650--74/50--7412.514.20.511*RARB*Cho YH, 2015 \[[@CR39]\]MethyLight (%)1021/1036na/na3339\>0.05Two studies reported no significant differences in methylation of *RARB* between BC cases and healthy controls.Cho YH, 2010 \[[@CR27]\]MethyLight (%)40/4050.8/48.31010\>0.05*APC*Zmetakova I, 2013 \[[@CR42]\]Pyrosequencing (mean ± SD)34/5041--90/20--781.68 ± 1.041.28 ± 0.570.082Two studies reported no significant differences in methylation of *APC* between BC cases and healthy controls.Cho YH, 2010 \[[@CR27]\]MethyLight (%)40/4050.8/48.300\>0.05*RASSF1A*Zmetakova I, 2013 \[[@CR42]\]Pyrosequencing (mean ± SD)34/5041--90/20--781.00 ± 0.001.04 ± 0.280.475Two studies reported no significant differences in methylation of *RASSF1A* between BC cases and healthy controls.Cho YH, 2010 \[[@CR27]\]MethyLight (%)40/4050.8/48.383\>0.05*na* not available^a^All studies were case--control study^b^Age indicates mean age or range

Figure [3](#Fig3){ref-type="fig"} shows the associations of gene-specific methylation in blood and BC risk. Yang et al. \[[@CR21]\] showed that reduced methylation levels of the *HYAL2* gene were significantly associated with increased BC risk. Specifically, women in the highest quartile of *HYAL2* methylation were reported to have a 41.47-fold (cohort I) and a 132.98-fold (cohort II) increased BC risk, compared with women in the lowest quartile (Fig. [3a](#Fig3){ref-type="fig"}). Hypermethylation of *ATM* and increased BC risk were observed in two studies \[[@CR15], [@CR17]\]. Here, the lowest methylation quantile was used as reference (Fig. [3b](#Fig3){ref-type="fig"}). Hoffman et al. observed a negative association between *CLOCK* methylation and BC risk \[[@CR28]\] (Fig. [3b](#Fig3){ref-type="fig"}). Widschwendter et al. investigated methylation of a few genes in a case--control study (*n* = 1083) and found that decreased DNA methylation in *NUP155 (I)*, *ZNF217 (II)*, *PTGS2*, *TITF1*, *NEUROD1*, and *SFRP1* are associated with increased BC risk \[[@CR14]\] (Fig. [3c](#Fig3){ref-type="fig"}). Hypermethylation of *BRCA1* promoter was associated with increased BC risk, which was confirmed in two independent studies \[[@CR16], [@CR37]\] (Fig. [3c](#Fig3){ref-type="fig"}).Fig. 3Associations of gene-specific methylation in blood and BC risk. **a** Studies used the highest methylation quantile as reference. **b** Studies used the lowest methylation quantile as reference. **c** Studies used methylation of controls as reference. ^a^The upper limit of 95% CI of the study of Gupta was over ten. ^b^Widschwendter M and coauthors investigated the genes from *ZNF217* to *TIMP3*

Gene-specific methylation in cfDNA from serum or plasma of BC cases and controls {#Sec10}
--------------------------------------------------------------------------------

Table [4](#Tab4){ref-type="table"} summarizes all studies that investigated methylation differences of specific genes in serum or plasma DNA of BC cases and healthy controls. Studies conducted by Yazici et al. \[[@CR46]\] and Brooks et al. \[[@CR56]\] were nested case--control studies and the remaining studies were all case--control studies. Generally, the sample sizes were rather low. Case number varied from 4 to 250. All eligible studies using serum or plasma DNA investigated DNA methylation levels at specific loci, rather than global DNA methylation levels. Further, so far no epigenome-wide study has been performed on cfDNA. This can be explained by the technical difficulties due to the specific characteristics, such as strongly fragmented DNA and reduced DNA integrity especially in cancer cases \[[@CR61]\]), and limited amounts of cfDNA that can be isolated from serum or plasma \[[@CR62]--[@CR64]\], and also to uncertainties regarding its origins \[[@CR65]\]. The most common method used to measure the methylation levels of specific genes in serum or plasma cfDNA was methylation-specific PCR (MSP) (Table [4](#Tab4){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2).Table 4Gene-specific methylation in serum or plasma DNA in breast cancer cases and controls investigated in more than one studyGeneAuthor, year \[ref\]SampleAssay (value)Case no./control no.Case age/control age (y)^b^Meth (case)Meth (control)*p* valueMain findings*RASSF1A*Kloten V, 2013 \[[@CR58]\]SerumMS-PCR (%)136/13533--86/33--8647.125.90.004Higher frequency of methylated *RASSF1A* was observed in eight studies. Studies by Zmetakova I et al. and Brooks JD et al. reported no significant differences in methylation of *RASSF1A* between cases and controlsZmetakova I, 2013 \[[@CR42]\]PlasmaPyrosequencing (mean ± SD)34/5041--90/20--782.85 ± 3.134.02 ± 6.620.404Ahmed IA, 2010 \[[@CR55]\]SerumMSP (%)26/1235--73/35--7369\<10--Brooks JD, 2010 \[[@CR56]\]^d^SerumQMSP (%)50/9952/51.82217.2\>0.05Kim JH, 2010 \[[@CR57]\]SerumQMSP (%)119/12551/5132.84.80.004Yazici H, 2009 \[[@CR46]\]^d^PlasmaMSP (%)61/39na/na185--Hoque M, 2006 \[[@CR44]\]PlasmaQMSP (%)47/3844.9/37.33250.002Van der Auwera I, 2009 \[[@CR52]\]SerumQMSP (%)79/1962/393500.002Papadopoulou E, 2006 \[[@CR45]\]PlasmaMethylight (%)50/14na/na260\<0.05Dulaimi E, 2004 \[[@CR50]\]SerumMSP (%)34/2057.4/57.4560\<0.05^c^*APC*Swellam M, 2015 \[[@CR59]\]SerumMS-PCR (%)121/6643/4093.40\<0.0001Five out of these seven studies reported higher frequency of methylated *APC* in BC patients. Studies by Zmetakova I et al. and Brooks JD et al. reported no significant differences in methylation of APC between cases and controls.Zmetakova I, 2013 \[[@CR42]\]PlasmaPyrosequencing (mean ± SD)34/5041--90/20--784.41 ± 7.812.53 ± 1.560.06Radpour R, 2011 \[[@CR47]\]PlasmaEpiTyper assay (mean)36/3067/na0.39^b^0.19^b^\<0.0001Brooks JD, 2010 \[[@CR56]\]^d^SerumQMSP (%)49/9652/51.824.2\>0.05Hoque M, 2006 \[[@CR44]\]PlasmaQMSP (%)47/3844.9/37.31700.008Van der Auwera I, 2009 \[[@CR52]\]SerumQMSP (%)79/1962/392950.03Dulaimi E, 2004 \[[@CR50]\]SerumMSP (%)34/2057.4/57.4290\<0.05^c^*ESR1*Zmetakova I, 2013 \[[@CR42]\]PlasmaPyrosequencing (mean ± SD)34/5041--90/20--784.18 ± 4.075.24 ± 4.330.338Only one study (Matinez-Galan, J) reported higher methylation levels of *ESR1* in BC patients. Others observed no significant methylation differences.Zurita M, 2010 \[[@CR54]\]SerumQMSP (%)77/34na/na0.005^b^0.085^b^\>0.05Van der Auwera I, 2009 \[[@CR52]\]SerumQMSP (%)79/1962/392010.50.33Martinez-Galan J, 2008 \[[@CR51]\]SerumMSP (%)106/7458/420.11^b^0.02^b^0.011*RARB*Swellam M, 2015 \[[@CR59]\]SerumMS-PCR (%)121/6643/4095.90\<0.0001Higher frequency of methylated *RARB* was observed except the study conducted by Brooks JD et al.Brooks JD, 2010 \[[@CR56]\]^d^SerumQMSP (%)45/8852/51.86.71.1\>0.05Kim JH, 2010 \[[@CR57]\]SerumQMSP (%)119/12551/5186.66.4\<0.001Hoque M, 2006 \[[@CR44]\]PlasmaQMSP (%)47/3844.9/37.32680.03*GSTP1*Radpour R, 2011 \[[@CR47]\]PlasmaEpiTyper assay (mean)36/3067/na0.52^b^0.39^b^0.003Two studies reported higher methylation level (Radpour R et al., 2011) or frequency (Hoque M et al., 2006) of *GSTP1* in BC patients. Study by Brooks.J.D observed no significant differences.Brooks JD, 2010 \[[@CR56]\]^d^SerumQMSP (%)50/9952/51.847.1\>0.05Hoque M, 2006 \[[@CR44]\]PlasmaQMSP (%)47/3844.9/37.32600.0008*SFN*Zurita M, 2010 \[[@CR54]\]SerumQMSP (%)77/34na/na0.002^b^0.1^b^\<0.001Both studies reported higher methlyation of *SFN* in BC patients.Martinez-Galan J, 2008 \[[@CR51]\]SerumMSP (%)106/7458/420.20^b^0.075^b^0.0047*BRCA1*Liu LM, 2015 \[[@CR60]\]SerumBisulfite sequencing PCR and MS-HRM (%)36^a^/30^a^na/na101.7\<0.05Both studies reported higher methlyation of *BRCA1* in BC patientsRadpour R, 2011 \[[@CR47]\]PlasmaEpiTyper assay36/3067/na0.58^b^0.30^b^\<0.0001*CST6*Chimonidou M, 2013 \[[@CR49]\]PlasmaMSP (%)73/37na/na16.40ChimonidouM et al. reported that *CST6* promoter is highly methylated in cfDNA of breast cancer patients, but not in healthy individuals. Radpour R et al. observed higher methlytion level of *CST6* in BC patients.Radpour R, 2011 \[[@CR47]\]PlasmaEpiTyper assay (mean)36/3067/na0.62^b^0.42^b^\<0.002*DAPK*Ahmed IA, 2010 \[[@CR55]\]SerumMSP (%)26/1235--73/35--7388\<10%\<0.05Higher frequency of methylated *DAPK* in patients was observed in both studies.Dulaimi E, 2004 \[[@CR50]\]SerumMSP34/2057.4/57.4350\<0.05^c^*TIMP3*Zmetakova I, 2013 \[[@CR42]\]PlasmaPyrosequencing (mean ± SD)34/5041--90/20--783.97 ± 8.433.92 ± 4.540.697Zmetakova I et al. reported no significant difference in methylation of *TIMP3* between patients and healthy controls. Radpour R et al. observed higher methylation level of *TIMP3* in BC patients.Radpour R, 2011 \[[@CR47]\]PlasmaEpiTyper assay36/3067/na0.60^b^0.50^b^\<0.0001*MSP* methylation-specific PCR, *QMSP* quantitative methylation-specific PCR, *MS-HRM* methylation-sensitive high-resolution melting, *na* not available^a^Age indicates mean age or range^b^Data was extracted from scatter plots or boxplots in the article^c^ *p* values were calculated by Fisher's exact test^d^Nested case--control study; the others are case--control study

Most of these studies investigated tumor suppressor genes and frequently reported the hypermethylation of these genes in BC patients (Table [4](#Tab4){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2). With ten studies, *RASSF1A* was the most frequently evaluated gene and eight of them reported higher frequency of methylated *RASSF1A* in BC patients compared to controls \[[@CR42], [@CR44]--[@CR46], [@CR50], [@CR52], [@CR55]--[@CR58]\]. *APC* has been investigated in seven studies \[[@CR42], [@CR44], [@CR47], [@CR50], [@CR52], [@CR56], [@CR59]\]. Among them, five studies reported higher frequency of methylated *APC* in plasma/serum DNA of BC patients. Higher frequency of methylated *RARB* (also known as *RARβ2*) was observed in four studies \[[@CR44], [@CR56], [@CR57], [@CR59]\]. Methylation levels of *ESR1* \[[@CR42], [@CR51], [@CR52], [@CR54]\], *GSTP1* \[[@CR44], [@CR47], [@CR56]\], and *TIMP3* \[[@CR42], [@CR47]\] were each investigated in two or more studies, but each gene yielded with inconclusive results. Hypermethylation of *SFN* (also known as stratifin or *14-3-3-σ*) \[[@CR51], [@CR54]\], *BRCA1* \[[@CR47], [@CR60]\], *CST6* \[[@CR47], [@CR49]\], and *DAPK* \[[@CR49], [@CR50]\] were confirmed in two independent studies, respectively (Table [4](#Tab4){ref-type="table"}). Brooks J.D. et al. \[[@CR56]\] reported no significant differences in the methylation of all four genes (*RASSF1A*, *GSTP1*, *APC*, and *RARB*) investigated between BC cases and controls. It is worth to point out that the DNA amounts used in this study were about five times less than the amount hypothetically required to achieve optimal sensitivity and non-specific amplification might occur due to a high number of PCR cycles (i.e., quantitative MSP (QMSP) was run for 50 cycles), as the authors discussed in the article. The authors observed lower frequency of methylation than expected among cases and higher than expected among controls in this study as compared to other studies (review in \[[@CR66]\]), which might be the reasons for the negative results. Other genes, which were investigated in only one study, were summarized in Additional file [1](#MOESM1){ref-type="media"}: Table S2.

Discussion {#Sec11}
==========

Our literature review identified 45 articles investigating blood-based DNA methylation markers for BC detection or risk evaluation, with DNA isolated from whole blood or from serum or plasma. In this systematic review, we summarized the differences in epigenome-wide DNA methylation levels or gene-specific methylation that were between BC patients and healthy females in all these studies. In particular, several large nested or respective case--control studies were conducted in recent years. This could be partly attributed to the novel emerging techniques, such as Infinium Humanmethylation 27K or 450K array or whole genome bisulfite sequencing (WGBS), which are effective ways to screen for and identify large numbers of methylation markers.

Even though whole blood DNA presents a mixture of leucocytes subtypes, DNA methylation from whole blood samples seems to be promising reservoir for informative biomarkers for BC risk stratification. Two nested case--control studies have concluded that such genomic hypomethylation continuum can be evident at blood DNA level and may identify high-risk women before developing BC \[[@CR18], [@CR19]\]. Some retrospective case--control studies also reported that cancer patients have lower global methylation levels in blood DNA compared to controls (Table [2](#Tab2){ref-type="table"}). As blood DNA can be assessed easily, its epigenetic effects on cancer propensity could be repeatedly examined in specified time intervals.

Repetitive DNA sequences (e.g., LINE-1, Alu, and Sat2) are all comparatively rich in CpG dinucleotides and contain a large portion of total methylcytosine levels in the genome \[[@CR67], [@CR68]\]. In this regard, some researchers suggested that repetitive elements in blood DNA might be surrogate for genomic hypomethylation. Studies of BC, however, have yielded heterogeneous results (Table [2](#Tab2){ref-type="table"}). Choi et al. \[[@CR26]\] found decreased methylation of 5-mdC in blood DNA of women with BC compared to controls; meanwhile, Wu HC et al. \[[@CR31]\] and Cho et al. \[[@CR27]\] found decreased methylation of Sat2 in BC patients. Xu et al. \[[@CR29]\], however, found increased global methylation among cases using the luminometric methylation assay. In the study of Choi et al., LINE-1 methylation and %5-mdC were not correlated, and only hypomethylation quantified as %5-mdC level was significantly associated with BC risk \[[@CR26]\]. The inconsistencies between results in BC patients and normal females probably arise from different detection targets, using different techniques and/or from differential distributions of clinical characteristics.

In the implementation and interpretation of studies based on blood samples, a potential limitation deserving particular attention is that differences in methylation profiles might also reflect differences in the proportions of the leukocyte subpopulations that make up the whole blood \[[@CR69], [@CR70]\]. Hence, the majority of EWASs adjusted their analysis for leucocyte distribution with the algorithm of Houseman et al. \[[@CR69]\]. Nevertheless, even if BC-related methylation patterns were partly due to confounding by leucocyte distribution, they might still be useful as biomarkers of BC.

Circulating cfDNA is defined as extracellular DNA occurring in blood. Both plasma and serum are cell-free blood specimens that were used for the determination of cfDNA. Silencing of tumor suppressor genes by promoter hypermethylation is known to be a frequent and early event in carcinogenesis \[[@CR11]\]. Further, changes in methylation patterns observed in tumors are also detectable in cfDNA of women with BC and showed good concordance \[[@CR50], [@CR71]--[@CR74]\]. This makes the possibility of using these alterations candidate markers for early tumor detection. Among all the identified studies in our review, the largest number of studies was found for *BRCA1* and *RASSF1A*, for which higher frequencies of methylated *BRCA1* and *RASSF1A* in BC patients than in healthy females were reported rather consistently. Other tumor suppressor genes, such as *APC*, *RARB*, *GSTP1*, *DAPK*, and *SFN* were also found more frequently methylated in BC cases than in controls. Methylation-specific PCR was the most frequently employed method in the studies evaluating the methylation of specific genes in whole blood and plasma/serum.

Circulating cfDNA, presumably shed from the original primary tumor, can be retrieved and tested for genetic and epigenetic alterations. However, so far, little is known about the relationship between detection of epigenetic abnormalities in primary BC tissue and detection of such abnormalities in plasma or serum. In addition, the amount of cfDNA is around 5--20 ng/ml in the circulation of a normal individual \[[@CR62], [@CR75]\], which strongly depends on the accurate sample processing \[[@CR61]\]. This could be the main obstacle in finding tumor-specific differences in sera/plasma and the main reason of the lack of sensitivity of the epigenetic biomarkers studied \[[@CR42]\]. cfDNA may be released to the circulation via passive release as a result of cellular apoptosis and necrosis and/or active secretion from live cells. The cfDNA can comprise long fragments or shorter fragments ranging from around 20 to 20 kb, depending on their mechanism of release into the circulation \[[@CR63], [@CR64]\]. It has been shown by experiments on fetal DNA in the maternal circulation that the half-life of free DNA in blood is only around 16 min \[[@CR76]\]. The limited amount, intrinsic characteristics, and short half-life of cell-free DNA could partly explain that for the markers evaluated in more than one study, the methylation differences between cases and controls are not consistent and sometimes varied greatly across studies. The discrepancy probably could also arise from diverse study design, use of different sources of DNA, and/or from differential distributions of clinical characteristics.

Changes in DNA methylation profiles, both at overall genomic level and specific loci, have been associated with BC risk (Fig. [2](#Fig2){ref-type="fig"} and Fig. [3](#Fig3){ref-type="fig"}). Among all the studies included in the present review, in total, eight studies measured overall WBC global DNA methylation and BC risk (Fig. [2](#Fig2){ref-type="fig"}). Four of these studies \[[@CR18], [@CR19], [@CR26], [@CR38]\] have found a significant elevated risk for BC between those in the lowest quantile of global DNA methylation compared to those in the highest methylation quantile. However, Kuchiba A et al. \[[@CR36]\] and Xu X et al. \[[@CR29]\] found a positive association between LUMA methylation and increased BC risk. The few studies investigating the gene-specific methylation in blood DNA also supported the potential for gene-specific methylation as biomarkers for risk (Fig. [3](#Fig3){ref-type="fig"}). However, research in this field is still at an early stage. So far, the number of studies that conducted epigenome-wide studies to detect BC associated genes is very limited. More evidence, including both genome-wide hypomethylation level and gene-specific hypo- and hypermethylation and BC risk, is still needed to collect.

BC is a highly heterogeneous disease. Many of the established risk factors are linked to the development of the disease. The highest risk factor for sporadic BC is increasing age. The incidence of BC in women doubles for every 10 years until menopause with a relative risk of \>10-fold \[[@CR77]\]. Because promoter hypermethylation may be related to age, studies investigating a potential diagnostic utility for methylated genes should have a reasonable number of age-matched controls. While some authors chose an age-matched control group, others did not and the age difference between cases and controls was often rather large. For example, Zmetakova I et al. \[[@CR42]\] compared BC patients with age range between 41 and 90 years with healthy blood donors of considerably younger age (range 20--78). The control group of the study conducted by Ito Y et al. \[[@CR25]\] even had an average of 43.2, which is almost 10 years younger than the mean age of BC patients (52.6) they included. Thus, the observed methylation differences and associations between methylation changes and BC risk might be confounded by age.

To our knowledge, this is the first review to systematically and comprehensively review and summarize results of epidemiological studies on the association of DNA methylation in blood with BC. In the interpretation of this review, some limitations have to be considered. Although two widely used databases were searched and cross-referencing of identified articles was applied, we cannot exclude having missed relevant studies. Furthermore, studies were reported in a rather heterogeneous manner, which limited possibilities of a standardized summary of the results. Because of the heterogeneous nature of the included studies and the fact that quite a few markers were evaluated in single studies only, we did not conduct meta-analyses and our tables only provide a narrative summary of the reported methylation differences.

Conclusions {#Sec12}
===========

Our review suggests the possibility of using blood-based methylation markers for risk stratification or the early detection of BC, as a number of studies support an association between methylation changes in blood and BC risk, irrespective of full understanding of the pathophysiological mechanisms. However, the evidence is still very limited. Optimized marker panels are yet to be developed and promising candidate markers needed to be validated in prospective study cohorts and tested in large screening populations by high quality studies. In addition, there is a strong need for large, methodologically rigorous epidemiological studies to figure out the potential role of methylation changes in blood in breast carcinogenesis and their implications for detection. Especially, the investigation of methylation changes in cfDNA holds great promises. Here, optimization of methods for genome-wide methylation analysis of small amounts of DNA is needed.
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5-mdC

:   5-Methyldeoxycytosine

BC

:   Breast cancer

CA15-3

:   Cancer antigen 15-3

CA27-29

:   Cancer antigen 27-29

cfDNA

:   Cell-free DNA

LC-MS

:   Liquid chromatography-mass spectrometry

LINE-1

:   Long interspersed nuclear element-1

LUMA

:   Luminometric methylation assay

MSP

:   Methylation-specific PCR

OR

:   Odds ratio

QMSP

:   Quantitative methylation-specific PCR

Sat2

:   Satellite 2
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